UCB
biopharmaceutical company headquartered in Brussels, Belgium
UCB Euronext Brussels · home listing
UCBJF OTC Markets Group
ISIN BE0003739530 LEI 2138008J191VLSGY5A09
Follow UCB
Weekly email: filings, results
Revenue, last year
€6.2B
+17.1% vs prior year
Net income
€1.1B
+210.5% vs prior year
EPS, diluted
€5.48
+211.4% vs prior year
Operating cash flow
€1.2B
+63.2% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY24 | €6.2B | €1.1B |
| FY23 | €5.3B | €343M |
| FY22 | €5.5B | €418M |
| FY21 | €5.8B | €1.1B |
| FY20 | €5.3B | €732M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY24 | 71.5% | 21.5% | 17.3% |
| FY23 | 67.5% | 11.5% | 6.5% |
| FY22 | 69.7% | 10.6% | 7.6% |
| FY21 | 75.1% | 22.2% | 18.3% |
| FY20 | 74.5% | 18.2% | 13.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY24 | €1B |
| FY23 | €523M |
| FY22 | €867M |
| FY21 | €1.3B |
| FY20 | €825M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY24 | €259M | €162M |
| FY23 | €252M | €40M |
| FY22 | €247M | €42M |
| FY21 | €240M | €60M |
| FY20 | €235M | €106M |
- UCB
- Healthcare median
Show the numbers
| Year | UCB | Healthcare median |
|---|---|---|
| FY24 | 17.3% | −47% |
| FY23 | 6.5% | −58% |
| FY22 | 7.6% | −80.4% |
| FY21 | 18.3% | −71.9% |
| FY20 | 13.7% | −62.2% |